Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for patients with unmet medical needs. The Company is engaged in developing R-107 for the treatment of vaccine-resistant corona virus disease (COVID) strains. R-107 is a patented nitric oxide-releasing compound for treatment of Covid-19 infection and possible prevention of, other viral infections. R-107 is designed to augment the body's natural release of nitric oxide to significantly hasten and strengthen the body's ability to combat viruses. IT is also developing CLA-1816 to provide effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
More about the company